Analyst Downgrades for Friday: Keysight, Akero Therapeutics, and More
ByAinvest
Friday, Oct 10, 2025 3:34 pm ET1min read
AKRO--
Wall Street analysts have recently downgraded several top names, including Akero Therapeutics, HSBC Holdings, Doximity, Keysight Technologies, and Allogene Therapeutics. The downgrades were made by HC Wainwright & Co., Jefferies, JP Morgan, Morgan Stanley, and JP Morgan, respectively. The analysts cited various reasons for the downgrades, including concerns about the companies' growth prospects and valuation multiples.
HC Wainwright & Co. analyst Andrew S. Fein downgraded Akero Therapeutics, Inc. (NASDAQ:AKRO) from Buy to Neutral and cut the price target from $72 to $54. This move comes amidst the announcement of Novo Nordisk's acquisition of Akero for up to $5.2 billion, which could impact the stock's valuation [2].
Jefferies analyst Joseph Dickerson downgraded the rating for HSBC Holdings plc (NYSE:HSBC) from Buy to Hold. The downgrade reflects concerns about the bank's growth prospects and valuation multiples [1].
JP Morgan analyst Alexei Gogolev downgraded Doximity, Inc. (NYSE:DOCS) from Neutral to Underweight and announced a $62 price target. The downgrade is attributed to concerns about the company's growth prospects and valuation [1].
Morgan Stanley analyst Meta Marshall downgraded Keysight Technologies, Inc. (NYSE:KEYS) from Overweight to Equal-Weight and maintained the price target of $180. The downgrade indicates a change in the analyst's view on the company's growth prospects [1].
JP Morgan analyst Brian Cheng downgraded Allogene Therapeutics, Inc. (NASDAQ:ALLO) from Neutral to Underweight. The downgrade is driven by concerns about the company's growth prospects and valuation [1].
These downgrades highlight the evolving views of Wall Street analysts on several key companies. Investors should closely monitor these developments and consider the implications for their portfolios.
ALLO--
DOCS--
HSBC--
KEYS--
Wall Street analysts have downgraded several top names, including Akero Therapeutics, HSBC Holdings, Doximity, Keysight Technologies, and Allogene Therapeutics. The downgrades were made by HC Wainwright & Co., Jefferies, JP Morgan, Morgan Stanley, and JP Morgan, respectively. The analysts cited various reasons for the downgrades, including concerns about the companies' growth prospects and valuation multiples.
September 12, 2025Wall Street analysts have recently downgraded several top names, including Akero Therapeutics, HSBC Holdings, Doximity, Keysight Technologies, and Allogene Therapeutics. The downgrades were made by HC Wainwright & Co., Jefferies, JP Morgan, Morgan Stanley, and JP Morgan, respectively. The analysts cited various reasons for the downgrades, including concerns about the companies' growth prospects and valuation multiples.
HC Wainwright & Co. analyst Andrew S. Fein downgraded Akero Therapeutics, Inc. (NASDAQ:AKRO) from Buy to Neutral and cut the price target from $72 to $54. This move comes amidst the announcement of Novo Nordisk's acquisition of Akero for up to $5.2 billion, which could impact the stock's valuation [2].
Jefferies analyst Joseph Dickerson downgraded the rating for HSBC Holdings plc (NYSE:HSBC) from Buy to Hold. The downgrade reflects concerns about the bank's growth prospects and valuation multiples [1].
JP Morgan analyst Alexei Gogolev downgraded Doximity, Inc. (NYSE:DOCS) from Neutral to Underweight and announced a $62 price target. The downgrade is attributed to concerns about the company's growth prospects and valuation [1].
Morgan Stanley analyst Meta Marshall downgraded Keysight Technologies, Inc. (NYSE:KEYS) from Overweight to Equal-Weight and maintained the price target of $180. The downgrade indicates a change in the analyst's view on the company's growth prospects [1].
JP Morgan analyst Brian Cheng downgraded Allogene Therapeutics, Inc. (NASDAQ:ALLO) from Neutral to Underweight. The downgrade is driven by concerns about the company's growth prospects and valuation [1].
These downgrades highlight the evolving views of Wall Street analysts on several key companies. Investors should closely monitor these developments and consider the implications for their portfolios.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet